{"preliminary_commentary":{"by_channel":{"x_thread":26,"youtube":19,"podcast":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04091126\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["belantamab mafodotin","bortezomib","lenalidomide","dexamethasone"]],"indication":"newly diagnosed multiple myeloma","name":"DREAMM-9","nct_id":"NCT04091126","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dreamm-9-nct04091126. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"DREAMM 9","arms":[{"description":"Participants will receive 1.9 milligram /kilogram (mg/kg) Q3W dose of belantamab mafodotin on Day 1 of every cycle for the first 8 cycles in combination with VRd and Q4W dose in combination with Rd from cycle 9 onwards.","label":"Cohort 1: belantamab mafodotin 1.9 mg/kg Q3/4W + VRd/Rd","type":"EXPERIMENTAL"},{"description":"Participants will receive 1.4 mg/kg Q6W dose of belantamab mafodotin on Day 1 of every other cycle for the first 8 cycles in combination with VRd and Q8W dose in combination with Rd from cycle 9 onwards.","label":"Cohort 2: belantamab mafodotin 1.4 mg/kg Q6/8W + VRd/Rd","type":"EXPERIMENTAL"},{"description":"Participants will receive 1.9 mg/kg Q6W dose of belantamab mafodotin on Day 1 of every other cycle for the first 8 cycles in combination with VRd and Q8W dose in combination with Rd from cycle 9 onwards.","label":"Cohort 3: belantamab mafodotin 1.9 mg/kg Q6/8W + VRd/Rd","type":"EXPERIMENTAL"},{"description":"Participants will receive 1.0 mg/kg Q3W dose of belantamab mafodotin on Day 1 of every cycle for the first 8 cycles in combination with VRd and Q4W dose in combination with Rd from cycle 9 onwards.","label":"Cohort 4: belantamab mafodotin 1.0 mg/kg Q3/4W + VRd/Rd","type":"EXPERIMENTAL"},{"description":"Participants will receive 1.4 mg/kg Q3W dose of belantamab mafodotin on Day 1 of every cycle for the first 8 cycles in combination with VRd and Q4W dose in combination with Rd from cycle 9 onwards.","label":"Cohort 5: belantamab mafodotin 1.4 mg/kg Q3/4W + VRd/Rd","type":"EXPERIMENTAL"},{"description":"Based on emerging data from Cohort 2-5, participants will receive 1.4 mg/kg dose of belantamab mafodotin on Day 1 of cycle 1, followed by 1.0 mg/kg dose on Day 1 of every third cycle from cycle 4 onwards, in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.","label":"Cohort 6: belantamab mafodotin 1.4mg/kg cycle 1, 1.0 mg/kg Q9/12W Cycle 4+VRd/Rd","type":"EXPERIMENTAL"},{"description":"Based on emerging data from Cohort 2-5, participants will receive 1.9 mg/kg dose of belantamab mafodotin of cycle 1, followed by 1.4 mg/kg on Day 1 of every third cycle from cycle 4 in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.","label":"Cohort 7: belantamab mafodotin 1.9 mg/kg Cycle 1, 1.4 mg/kg Q9/12W Cycle 4+VRd/Rd","type":"EXPERIMENTAL"},{"description":"Based on emerging data from Cohort 6-7, participants will receive 1.9 mg/kg dose of belantamab mafodotin on Day 1 of cycle 1 and cycle 4, followed by 1.4 mg/kg on Day 1 of every third cycle from cycle 7 onwards, in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.","label":"Cohort 8a : belantamab mafodotin 1.9 mg/kg Cycle 1,4; 1.4 mg/kg Q9/12W from Cycle 7 +VRd/Rd","type":"EXPERIMENTAL"},{"description":"Based on emerging data from Cohort 6-7, participants will receive 1.4 mg/kg IV dose of belantamab mafodotin on Day 1 of cycle 1 and cycle 3, then 1.0 mg/kg on Day 1 of every third cycle from cycle 6 in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.","label":"Cohort 8b: belantamab mafodotin 1.4 mg/kg Cycle 1,3; 1.0 mg/kg Q9/12W from Cycle 6 +VRd/Rd","type":"EXPERIMENTAL"},{"description":"Based on emerging data from Cohort 6-7, participants will receive 1.0 mg/kg IV dose of belantamab mafodotin on Day 1 of cycle 1 and cycle 5, then 1.0 mg/kg on day 1 of every third cycle from cycle 9 in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.","label":"Cohort 8c: belantamab mafodotin 1.0 mg/kg Cycle 1,5;1.0 mg/kg Q9/12W from Cycle 9 +VRd/Rd","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":118,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Belantamab mafodotin","otherNames":[],"type":"DRUG"},{"name":"Bortezomib","otherNames":[],"type":"DRUG"},{"name":"Lenalidomide","otherNames":[],"type":"DRUG"},{"name":"Dexamethasone","otherNames":[],"type":"DRUG"}],"last_update":"2025-11-28","lead_sponsor":"GlaxoSmithKline","official_title":"A Phase 1, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Belantamab Mafodotin Administered in Combination With Standard of Care in Participants With Newly Diagnosed Multiple Myeloma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2025-06-02","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of participants with dose-limiting toxicities (DLTs)","timeFrame":"Treatment cycle 1 to 3 (each cycle of 21 days)"},{"measure":"Number of participants with adverse events (AEs) and serious adverse events (SAEs)","timeFrame":"Up to an average of 54 months"}],"references":[],"start_date":{"date":"2019-12-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT04091126"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dreamm-9-nct04091126"}